Novo Nordisk AS (WBO:NNO2) Cash Flow from Investing: €-11,369 Mil (TTM As of Mar. 2026)


WBO:NNO2 Novo Nordisk AS WBO:NNO2
71 GF Score
Price €43.06
GF Value €120.11
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Cash Flow from Investing?

Novo Nordisk AS WBO:NNO2 -1.23% 71 Cash Flow from Investing is €-11,369 Mil as of Mar. 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.11 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2026, Novo Nordisk AS spent €1,513 Mil on purchasing property, plant, equipment. It gained €0 Mil from selling property, plant, and equipment. It spent €0 Mil on purchasing business. It gained €6 Mil from selling business. It spent €0 Mil on purchasing investments. It gained €3 Mil from selling investments. It paid €97Mil for net Intangibles purchase and sale. And it received €35 Mil from other investing activities. In all, Novo Nordisk AS spent €1,567 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2026.


Novo Nordisk AS  (WBO:NNO2) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Novo Nordisk AS's purchase of property, plant, equipment for the three months ended in Mar. 2026 was €-1,513 Mil. It means Novo Nordisk AS spent €1,513 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Novo Nordisk AS's sale of property, plant, equipment for the three months ended in Mar. 2026 was €0 Mil. It means Novo Nordisk AS gained €0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Novo Nordisk AS's purchase of business for the three months ended in Mar. 2026 was €0 Mil. It means Novo Nordisk AS spent €0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Novo Nordisk AS's sale of business for the three months ended in Mar. 2026 was €6 Mil. It means Novo Nordisk AS gained €6 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Novo Nordisk AS's purchase of investment for the three months ended in Mar. 2026 was €0 Mil. It means Novo Nordisk AS spent {stock_data.stock.currency_symbol}}0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Novo Nordisk AS's sale of investment for the three months ended in Mar. 2026 was €3 Mil. It means Novo Nordisk AS gained €3 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Novo Nordisk AS's net Intangibles purchase and sale for the three months ended in Mar. 2026 was €-97 Mil. It means Novo Nordisk AS paid €97 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Novo Nordisk AS's cash from discontinued investing activities for the three months ended in Mar. 2026 was 0 Mil. It means Novo Nordisk AS paid €0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Novo Nordisk AS's cash from other investing activities for the three months ended in Mar. 2026 was €35 Mil. It means Novo Nordisk AS received €35 Mil from other investing activities.


Novo Nordisk AS Cash Flow from Investing Related Terms


Novo Nordisk AS Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Cash Flow from Investing Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,250.18 -3,349.41 -5,888.83 -17,283.49 -10,598.42

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -801.61 -2,002.89 -2,066.69 -5,732.07 -1,566.96
WBO:NNO2
71GF Score
Novo Nordisk AS WBO:NNO2
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Novo Nordisk AS's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

Novo Nordisk AS's Cash Flow from Investing for the quarter that ended in Mar. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11,369 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of €-11,369 Mil mean?
Novo Nordisk AS (WBO:NNO2) has a Cash Flow from Investing of €-11,369 Mil as of Mar. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cash Flow from Investing too high?
Novo Nordisk AS's current Cash Flow from Investing is €-11,369 Mil. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cash Flow from Investing compare to LLY and JNJ?
Novo Nordisk AS's Cash Flow from Investing of €-11,369 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Drug Manufacturers company?
A good Cash Flow from Investing depends on the Drug Manufacturers industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Novo Nordisk AS and its competitors. Novo Nordisk AS's current Cash Flow from Investing is €-11,369 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.11, compared to a current price of €43.06 — trading 64.2% below its estimated fair value. The current Cash Flow from Investing is €-11,369 Mil. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Cash Flow from Investing is €-11,369 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.06 is trading 64.2% below its estimated GF Value™ of €120.11. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • Cash Flow from Investing: €-11,369 Mil
  • GF Value™: €120.11 vs. price of €43.06 (64.2% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score

Get the complete analysis for WBO:NNO2

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.06
Price
€120.11
GF Value